Mometeva (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometeva, is a corticosteroid presented as a nasal spray for endosinusial use. It is used to reduce inflammation in the nasal passages of patients with allergic rhinitis, nasal polyps and other inflammatory nasal conditions.

GNH USA supplies Mometeva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometeva, a topical corticosteroid, is indicated for inflammatory conditions of the nasal mucosa.

Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhea. Nasal polyps: reduces polyp size and improves nasal airflow after surgery. Non‑allergic rhinitis: diminishes nasal inflammation and related symptoms.

Common Side Effects: - Nasal irritation or burning sensation - Epistaxis (nosebleeds) - Headache - Throat irritation or dryness - Cough - Altered taste perception

Serious or Rare Side Effects: - Adrenal suppression with prolonged use - Cataracts or glaucoma development - Severe allergic reaction (anaphylaxis) - Fungal infection of the nasal passages - Nasal septum perforation - Vision changes requiring urgent evaluation

Before using Mometeva, consider the following precautions: - Use only as prescribed: follow the prescriber's instructions for frequency and duration. - Avoid prolonged continuous use: limit treatment to the period recommended by a healthcare professional. - Monitor for signs of infection: discontinue if persistent fungal or bacterial infection occurs. - Caution in patients with glaucoma or cataracts: consult an eye specialist before use. - Post‑surgical nasal care: avoid use immediately after nasal surgery unless directed. - Store below 30°C: keep in the original container, protect from moisture and direct sunlight.

Mometasone furoate may interact with other medications as follows:

Major Interactions (Avoid): - Systemic corticosteroids: increased risk of adrenal suppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise systemic exposure. - Immunosuppressants: heightened immunosuppressive effect.

Moderate Interactions (Monitor Closely): - Antihistamines: may enhance sedative effects in sensitive individuals. - Antifungal agents (e.g., fluconazole): potential for modest exposure increase. - Ritonavir or other protease inhibitors: may require monitoring of systemic corticosteroid levels.